Bencyclane - A new aspect of the mechanism of action in patients with peripheral arterial occlusive disease. Open-label, prospective, randomized trial

Acta Angiologica

Volumn 11, Issue 3, 2005, Pages 157-172

  Bieroń, Krzysztof ^a   Kostka Tra̧bka, Elzbieta ^a   Starzyk, Dorota ^a   Goszcz, Aleksandra ^a   Grodzińska, Lilia ^a   Korbut, Ryszard ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Bencyclane; Nitric oxide; Pentoxifylline; Peripheral arterial occlusive disease; Prostacycline; Tissue plasminogen activator; Vascular endothelium

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANTITHROMBOCYTIC AGENT; BENCYCLANE; FIBRINOLYTIC AGENT; PENTOXIFYLLINE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; ENDOTHELIUM; ERYTHROCYTE DEFORMABILITY; HUMAN; ISCHEMIC PAIN; LIMB ISCHEMIA; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; VASODILATATION;

EID: 29444459763     PISSN: 1234950X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Cencora A, Jarosz Z, Gawlik A, Nowak K (1978) Halidor stosowany dotȩtniczo w miażdżycy zarostowej kończyn dolnych. Pro Memoria, 16: 27-31.
2. Cencora A (1980) Halidor w leczeniu choroby i zespotu Raynauda. Pro Memoria, 19: 21-25.
3. Cencora A (2004) Can everyday walking replace treadmil training in patients with claudication? Do Bencyclane fumarate or Xantinol nicotinate affect the results of such treatment? Open, randomized, prospective, comparative, one center-based-study. Acta Angiol, 10: 77-89.
4. Grodzińska L, Basista M, Dembińska-Kieć A, Kostka-Tra̧bka E (1989) Halidor (Bencyclan) w leczeniu zarostowego stwardnienia tȩtnic kończyn dolnych (stadium I i II). Pro Memoria, 23: 23-28.
5. Trübestein G, Trübestein R, Ludwig M (1989) Bencyclan bei arterieller Verschlusskrankheit im Stadium II. Ergebnisse einer kontrollierten Studie. Fortschr d Med, 107: 781-784.
6. Szekeres L (1970) Die hämodynamische Wirkung von Bencyclan. Arzneim Forsch, 20: 1362-1367.
7. Solti F (1970) Die Wirkung von Bencyclan auf die Blutdurchströmung der Extremitäten. Arzneim Forsch, 20: 1358-1360.
8. ++-antagonistische Hemmstoffe der elektro-mechanischen Koppelung wie Isoptin (Verapamil, Iproveratril), Substanz D 600 und Segontin (Prenylamin). Versuche am isolierten Uterus virgineller Ratten. Klin Wschr, 49: 32-41.
9. Brandt H, Schanzenbächer P, Enzenross HG, Betz E (1975) Die Auswirkungen erhöhter Kalziumkonzentrationem im künstlichen Liquor cerebrospinalis auf die Piagefassweite bei perivaskulärer Mikroperfusion und die Hemmwirkung durch Bencyclan. Arzneim-Forsch, 25: 1393-1396.
10. Nanasi PP, Varro A, Rabloczky G, Danko M (1987) Use-dependent blockade of sodium channels induced by bencyclane in frog skeletal muscle and canine cardiac Purkinje fiber. Arch Intnt Pharmacodyn Ther, 290: 278-287.
11. Nanasi PP, Bodnar Z, Danko M (1989) Effects of bencyclane on normal and cevadine-midified Na channels in frog skeletal muscle. Gen Physiol Biophys, 8: 447-458.
12. Kukovetz WR, Pöch G, Holzmann S, Paietta E (1975) Zum Wirkungsmechanismus von Bencyclan an der glatten Muskulatur. Arzneim-Forsch, 25: 722-726.
13. Wolski A, Terlecki P, Przywara S et al (2004) Ocena efektów leczenia przewlekłego niedokrwienia kończyn dolnych bencyklanem i pentoksyfilina̧. Chirurgia Polska, 6: suppl A.
14. Management of Peripheral Arterial Disease (PAD) (2000) TransAtlantic Inter-Society Consensus (TASC). Pharmacotherapy for Symptoms of Intermittent Claudication. J Vasc Surg, 31: 89-96.
15. Kaulla von KN, Schultz RL (1958) Methods for evaluation of human fibrinolysis. Am J Clin Pathol, 29: 104-112.
16. Wu KK, Hoak JC (1974) A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet, 2: 924-926.
17. Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 194: 927-929.
18. Aviado DM, Dettelbach HR (1984) Pharmacology of pentoxifylline a hemorheolic agent for the treatment of intermittent claudication. Angiology, 35: 407-417.
19. Hood SC, Moher D, Barber GG (1996) Management of intermittent claudication with pentoxifylline; meta-analysis of randomized controlled trials. CMAJ, 155: 1053-1059.
20. Porter JM, Cutler BS, Lee BY et al (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J, 104: 66-72.
21. Lindgarde F, Jelnes R, Bjorkman K et al (1989) Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation, 80: 1549-1556.
22. Kostka-Tra̧bka E, Dembińska-Kieć A, Grodzińska L et al (1983) Pentoxifylline (Trental) in the treatment of arteriosclerosis obliterans. Zbl Phar, 122: 763-765.
23. Kostka-Tra̧bka E, Dembińska-Kieć A, Grodzińska L, Bieroń K, Gryglewski RJ (1985) Beneficial results of pentoxifylline (Trental) therapy in arteriosclerosis obliterans: possible mechanism of action. Curr Med Res Opin, 9: 407-415.
24. Jawień A, Grzela T, Ciecierski M, Piotrowicz R, Szotkiewicz A, Migdalski A (2003) Buflomedil associated with pentoxifylline in the treatment of patients with intermittent claudication. Opened, randomised, one-centre-based study. Acta Angiol, 9: 109-122.
25. Gryglewski RJ, Grodzińska L, Kostka-Tra̧bka E et al (1996) The treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wiener Klin Woch Schr, 108: 111-116.
26. Mondillo S, Balla P, Barbati R et al (2003) Effect of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med, 114: 359-364.
27. De Nucci G, Gryglewski RJ, Warner TD, Vane JR (1988) Receptor-mediated release of endothelium-derived relaxing factor (EDRF) and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci, 85: 2334-2338.
28. Szczeklik A, Kopeć M, Sładek K (1983) Prostacyclin and the fibrinolytic system in ischaemic vascular disease. Thromb Res, 29: 655-660.
29. Musiał J, Wilczyńska M., Sładek K, Cierniawski CS, Niżankowski R, Szczeklik A (1986) Fibrinolytic activity of prostacyclin and iloprost i patients with peripheral arterial disease. Prostaglandins, 31: 61-70.
30. Korbut R, Lidbury PS, Vane JR (1990) Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet, 335: 669.
31. Lidbury PS, Korbut R, Vane JR (1990) Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br J Pharmacol, 101: 527-530.
32. Dembińska-Kieć A, Gryglewska T, Żmuda A, Gryglewski RJ (1977) The generation of prostacyclin by arteries and by vascular bed is reduced in experimental atherosclerosis i rabbits. Prostaglandins, 14: 1025-1035.
33. 2 biosynthesis capacities of heart, arteries and platelets of varius stages of experimental atherosclerosis. Atherosclerosis, 31: 385-394.
34. D'Angelo V, Mysliwiec M, Donati MB, De Gaetano G (1978) Defective fibrinolytic and prostacyclin-like activity in human atherromateous plaque. Tromb Haemostas, 39: 535-536.
35. Försterman U, Mugge A, Alheid U, Haverich A, Frölich JC (1988) Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res, 62: 185-190.
36. Gryglewski RJ (1990) Nitric oxide and atherosclerosis. Thromb Haemorrh Disorders, 2/1: 1-9.
37. Chester AH, O'Neil GS, Moncada S, Yacoub MH (1990) Low basal and simulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet, 336: 897-900.
38. Dembińska-Kiec A, Kostka-Tra̧ka E, Gryglewski RJ (1982) Effect of prostacyclin on fiibrinolytic activity in patents with arteriosclerosis obliterans. Thromb Haemostas, 47: 190.
39. 2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans. Pharm Res Commun, 14: 485-498.
40. Korbut R, Żmuda A, Basista M, Gryglewski RJ (1986) Eicosanoids balance at early stage of experimental atherosclerosis: its relationship with plasma fibrinolytic activity and platelet aggregation. Agents Actions, 20: 225.